Drugs / 225Ac-ABD147
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06736418 | Mar 2025 → Aug 2026 overdue | pulmonary large cell neuroendocrine carcinoma, small cell lung carcinoma | Abdera Therapeutics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 225Ac-ABD147 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06736418 ↗ |
| Target | DLL3 | “DLL3-targeting” NCT06736418 ↗ |